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Executive summary 
 
This study was commissioned as part of the ‘Fleming Fund: supporting surveillance capacity 
for antimicrobial resistance’ for the project ‘An analysis of networks and education 
resources supporting drug resistant infection surveillance in low and middle income 
countries (LMICs)’ (see annex 1).  The study objectives were to identify and describe drug 
resistance surveillance networks in LMICs and identify available educational resources that 
could support effective implementation of such networks.    
We defined an anti-microbial resistance (AMR) surveillance network as a group of 
institutions (nationally) or countries (regionally/globally) that gather, analyse, compile and 
share the results of any aspect of antimicrobial resistance (e.g. antimicrobial resistance, 
antimicrobial use and antimicrobial quality). Publications with potential descriptions of, or 
references to, LMIC anti-microbial resistance (AMR) surveillance networks and educational 
resources from January 2000 to June 2016 were sought from electronic databases and from 
individuals involved in, or with knowledge of, such networks. A data extraction tool was 
designed to capture all aspects of an AMR surveillance network which we identified from the 
literature and our own experience and that of others working in AMR surveillance in LMICs. 
Only educational resources that were freely available were accessed and their content, 
scope and origin were documented.  
Telephone interviews were conducted with key individuals associated with AMR surveillance 
networks that had been selected because the networks had national or international scope 
and represented a range of geographical locations and infections. Information collected 
covered data collection, technical support, training and external quality assurance. It also 
covered: mechanisms for sharing data, standard operating procedures and best practice; 
and barriers and enablers to the implementation and maintenance of the surveillance 
networks. Information was included on all the networks we identified but not all of the 
information was verified by interviews. This is important to note since it is possible that 
some of the identified networks may no longer be operational.  
Twenty regional and international AMR surveillance networks were identified. Most of these 
provided routine AMR surveillance in specific regions (i.e. Europe, US, Central Asia, Latin 
America and Eastern Europe) or globally on certain topics (i.e. paediatric infections, 
tuberculosis, HIV, pneumonia, meningitis, gonorrhoea). In addition to the routine 
surveillance networks, we identified several research networks involved in AMR surveillance.  
These covered general AMR in different regions (i.e. Asia) or specific target groups (i.e. 
paediatrics), or organisms (i.e. salmonella, TB, E coli, nosocomial). We also identified four 
AMR surveillance networks for infections transmitted through food, water and zoonoses.  
We identified a limited number of educational resources relevant for supporting AMR 
surveillance which are freely accessible on-line. These covered generic issues to do with 
AMR surveillance or public health surveillance in general and some focused on specific 
organisms or target groups such as data managers, laboratories or paediatricians. These 
resources will need to be reviewed by the different players involved in AMR surveillance so 
that it can be determined whether or not they meet their needs.   
The European EARS-NET model seems to have been successful and could be considered for 
expanding to other regions such as central Asia. Coordination of activities and sharing of 
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information across these three types of networks (routine, research, food/water/zoonoses) 
may be beneficial to maximise synergy and avoid duplication, particularly of laboratory 
testing. Africa seems to be particular poorly served in terms of AMR surveillance networks. 
In-depth analysis of some of the more and less successful AMR surveillance networks would 
be helpful in guiding future programmes about what works and does not work in different 
contexts.  
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Introduction 
 
This study was commissioned as part of the ‘Fleming Fund: supporting surveillance capacity 
for antimicrobial resistance’ for the project ‘An analysis of networks and education 
resources supporting drug resistant infection surveillance in low and middle income 
countries (LMICs)’ (see annex 1).  The study objectives (described in full in 2.1 and 2.2 below) 
were to identify and describe drug resistance surveillance networks in LMICs and identify 
available educational resources designed to support effective implementation of such 
networks.    
We defined an anti-microbial resistance (AMR) surveillance network as a group of 
institutions (nationally) or countries (regionally/globally) that gather, analyse, compile and 
share the results of any aspect of antimicrobial resistance (e.g. antimicrobial resistance, 
antimicrobial use and antimicrobial quality). The study activities covered:  
• A literature review to identify global AMR surveillance networks with a focus on LMICs 
• A description of the networks using a pre-designed matrix informed by existing AMR 
surveillance system literature including the WHO’s Global Antimicrobial Resistance 
Surveillance System (GLASS) (3) and the OASIS tool for assessing epidemiological 
surveillance systems (4).  
• Identification of challenges and successes in establishing and managing AMR 
surveillance networks with suggestions for how challenges may be addressed 
• Identification of educational resources to support AMR surveillance networks, including 
their content, access and format  
 
Methodology 
 
Literature Search 
 
Search strategy 
Publications with potential descriptions of, or references to, low and middle income country 
(LMIC) AMR surveillance networks and educational resources were sought from a search of 
the Medline, Web of Science, Global Health, PubMed, Google Scholar and Google databases. 
The reference period for the search was January 2000 to June 2016 and the search was 
limited to English language publications. Additional information on potential surveillance 
networks and educational resources were sought from a manual search of references listed 
in retrieved articles.  A Google search was also conducted to identify the web presence of 
relevant networks and resources and any associated documentation.  
 
Network and resources identification 
Retrieved publications, documents or reports were examined for references to AMR-
relevant LMIC surveillance networks and resources. In the first instance, 
publication/document/report titles, abstracts and key words were reviewed and the full text 
was retrieved for those which were relevant for AMR. All LMIC surveillance networks and 
resources identified during the course of the full text review were recorded on an Excel 
spreadsheet. Our research team sent formal requests to their existing professional contacts 
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asking them to identify relevant surveillance networks and resources and to identify other 
key informants (described below). These were added to the Excel spreadsheet.  
 
Data extraction 
The research team developed and piloted a data extraction tool designed to capture the 
information necessary to assess each of the identified LMIC surveillance networks and 
educational resources.  The components of the data extraction tool for AMR surveillance 
networks were based on the World Health Organisation’s (WHO) GLASS manual for early 
implementation of an AMR surveillance system (3) and the OASIS tool for assessing 
epidemiological surveillance systems (4). Research team members reviewed all documents 
pertaining to each of the identified LMIC surveillance networks identified during the 
literature search in order to populate the data extraction tool. Additional data were sought 
from standard internet searches using the respective network name as a search term and 
through information obtained from key informant interviews. Only educational resources 
that were freely available were accessed and their content, scope and origin were 
documented.  
 
Key Informant Interviews 
 
Key informant interviews (KIIs) were conducted with a senior member of purposively 
selected LMIC surveillance networks and/or with an individual familiar with a particular 
surveillance network. The networks were selected to provide a range of the major 
‘typologies’ of surveillance for AMR, and to have international or regional scope. Potential 
KIs were identified during the literature search, through existing professional networks or by 
other key informants themselves (i.e. ‘snowball’ recruitment).  An introductory email was 
sent to all prospective KIs in the first instance informing them about the study aims, 
requesting their participation and inviting them to identify a date/time for possible 
interview.  Prospective KIs who did not response to the email invitation were subsequently 
contacted by telephone, provided with more details about the study and invited to 
participate.  
 
All interviews were conducted by telephone and followed a structured topic guide, the 
contents of which were based on a review of relevant literature. The topic guide covered 
core functions of an AMR surveillance network (e.g. data collection, technical support, 
training, external quality assurance, and mechanisms for sharing data, standard operating 
procedures, and best practice). The interview guide also covered barriers and enablers to 
the implementation and maintenance of the surveillance networks, and solicited 
interviewees’ knowledge of other LMIC surveillance networks and educational/training 
resources designed to strengthen AMR surveillance capacity.  KIIs were audio-recorded 
when possible and when permission was granted and detailed written summary notes 
taken.  Recordings were used to check the accuracy of the notes. All relevant KII data were 
entered into a specifically-designed excel spreadsheet for subsequent analysis. Networks for 
which we were able to include data from KII are marked with an “*” on the relevant tables. 
Data not marked with “*” cannot therefore be considered verified and therefore cannot be 
considered complete or up to date. This is important since it is possible that some of the 
identified networks may no longer be operational.  
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Findings on educational resources for supporting anti-microbial 
resistance surveillance 
 
Twenty regional and international AMR surveillance networks were identified (tables 1, 2, 3 
and 4). We also identified military United State of America (USA) AMR networks that 
operated in LMICs but were not included since they only monitored USA military personnel. 
We also excluded the European Surveillance of Veterinary Antimicrobial Consumption as it 
did not deal with AMR surveillance.  
AMR surveillance in humans 
Networks providing routine surveillance 
European Antimicrobial Resistance Surveillance network 
European Antimicrobial Resistance Surveillance network (EARS-NET) collects surveillance 
data mainly for the European Union (EU), which includes some middle-income countries 
such as Bulgaria and Romania. EARS-NET countries use EUCAST, a WHO approved standard 
for anti-microbial susceptibility testing (AST). EARS-NET also provides an annual round of 
external quality assurance (EQA). Data collected by the network is stored on The European 
Surveillance System (TESSy) database, which provides open access to participating countries 
and some publicly accessible information. Data concerning a specified list of 
bacteria/specimens/antimicrobial agents under AMR surveillance are uploaded and the 
database creates one record per patient, bacterium, antimicrobial agent and year. 
EARS-NET has a co-ordinating committee to provide scientific support and coordinates with 
other related networks in the EU, namely the European Surveillance of Antimicrobial 
Consumption Network (ESAC-Net) and the Healthcare-Associated Infections Surveillance 
Network (HAI-Net).  
EARS-NET has the following objectives: 
 to collect comparable, representative and accurate AMR data; 
 to analyse temporal and spatial trends of AMR in Europe; 
 to provide timely AMR data for policy decisions; 
 to encourage the implementation, maintenance and improvement of national AMR 
surveillance programmes; and 
 to support national systems in their efforts to improve diagnostic accuracy by offering an 
annual EQA. 
Only data from invasive ‘priority specimens’ (blood and cerebrospinal fluid) isolates are 
included in EARS-NET. It does not collect data on a syndromic basis or for other types of 
specimens due to the increasing likelihood of confounders influencing the data (e.g. 
inconsistent use of clinical case definitions and different sampling frames). Blood culture 
sampling can also suffer from random sampling errors due to differences in the frequency of 
blood culture collection; this complicates the accuracy of comparisons between hospitals 
and countries. This limitation, and variations in population coverage, are acknowledged by 
EARS-NET.  
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US CDC Global Disease Detection programme (GDP) 
This purpose of the GDP is to detect outbreaks across the globe through ten global disease 
control centres. As part of this activity it may collect AMR data. It also supports a Field 
Epidemiology Training Programme.  
Central Asian and Eastern European Surveillance of AMR Network (CAESAR) 
Similar to EARS-NET this network collects data on eight organisms responsible for infections 
of cerebrospinal fluid and blood. According to the CAESAR 2014 report, five countries in the 
network have begun submitting data (Belarus, Serbia, Switzerland, the former Yugoslav 
Republic of Macedonia and Turkey). Another ten countries were in the process of submitting 
data. Like EARS-NET, CAESAR provides an annual EQA service to countries and promotes the 
EUCAST standard for AST.  
The CAESAR network has identified the following challenges:  
• limited human and financial resources to address the need for laboratory capacity 
building; 
• continuing need to educate laboratory personnel; 
• the need for implementation of updated guidelines on the standardization of antibiotic 
susceptibility testing (AST) (from the Clinical and Laboratory Standards Institute (CLSI) 
and EUCAST), laboratory methods for species identification and blood culturing; 
• the need for standard operating procedures and quality control in laboratory practice; 
• the need to improve sampling habits and utilization of medical microbiologic diagnostics 
in hospitals; and 
• the need to improve laboratory information management and set up an infrastructure 
for central data collection at a national reference laboratory. 
Workshops have been organised to try to address these challenges and laboratory twinning 
has been raised as a way to further improve capacity.  
Red Latinoamericana de Vigilancia a las Resistencias Antimicrobianis (ReLARVA) 
This network was launched in 1996 by WHO Pan-American Health Organization (PAHO) and 
obtains resistance data from 21 Latin American countries. The National Institute of 
Infectious Diseases of Argentina coordinates the network except for enteric pathogens, 
which are coordinated through the Canadian National Microbiology Laboratory for Enteric 
Pathogens. Representatives of national reference laboratories participate in a biennial 
meeting aimed at information sharing, standardization and networking.  
The network participates in external quality assurance programmes for bacteriology and 
AMR coordinated by the National Administration of Health Laboratories and Institutes. The 
majority of members use WHO-NET software for reporting AMR data, though it is not 
mandatory in the network. PAHO has commented that funding for the consolidation of the 
network is a challenge. 
Global Antimicrobial Resistance, Prescribing, and Efficacy Among Neonates and Children 
After a pilot phase this programme was launched in November 2015 and has been actively 
trying to expand the number of sites in its network. It has the following aims:  
• Characterisation of antimicrobial prescription rates among neonatal and paediatric 
patients using periodic point prevalence surveys 
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• Assessing blood stream infection burden and resistance patterns among neonatal and 
paediatric patients using routinely collected laboratory data 
Global Gonococcal Antimicrobial Surveillance Program (GASP) 
This re-established WHO programme has been collecting data on gonococcal resistance 
patterns since 2009. WHO Geneva coordinates this project with interregional collaborators 
in Africa, Asia, the Americas, Europe and the Western Pacific. Though many high-income 
countries have well developed GASPs, the programme recognises that LMICs require 
additional support to develop functional GASPs. 
The WHO Global Project on anti-tuberculosis drug resistance surveillance 
The WHO Global Project on anti-tuberculosis drug resistance surveillance has collected data 
on tuberculosis resistance from 144 countries since 1994. The data is published annually in 
the Global Tuberculosis Report and includes data from routine country surveillance and 
national drug resistance surveys. In LMICs, routine surveillance is normally restricted to 
patients at high risk from multi-drug resistant TB (MDR-TB) (e.g. previously treated cases). 
Hence, countries are advised by WHO to carry out periodic MDR TB surveys to determine 
drug resistance in all tuberculosis cases. Standards for the phenotypic and molecular 
detection of drug resistance have been developed but, particularly for phenotypic detection, 
it is not clear if these have been fully implemented at national level.  The TB supra-national 
network provides an EQA service, but its usage and hence the data it generates, can be 
erratic.  
Global HIV Drug Resistance Surveillance Network 
This WHO led network supports countries to conduct national surveillance surveys for HIV 
drug resistance (HIVDR). Their guidelines focus on the surveillance of HIVDR among patients 
starting first-line ART and on acquired HIVDR in populations experiencing virological failure 
while on first-line ART.  
System of Networks for Surveillance of the Bacterial Agents Responsible for Pneumonia and 
Meningitis (SIREVA II) 
This network focuses on vaccine-preventable bacterial causes of pneumonia and meningitis 
in Latin America in children under 5 years. It is coordinated by WHO-PAHO in partnership 
with Pfizer and GSK. Each participating country has sentinel sites to detect and culture 
isolates from children under 5 years. Suspected, probable and confirmed case definitions for 
pneumonia and meningitis have been agreed. There is a clearly laid out process for the 
reporting and sending of isolates and data to the national reference centres and for how 
these centres report to PAHO.  
PAHO operates an EQA programme that rechecks isolates and conducts proficiency testing 
through two sub-regional reference centres. Training is also provided to laboratory staff 
including on the proper shipment of isolates. Laboratory evaluations are also undertaken to 
monitor quality. 
Research Based Networks 
Asian Network for Surveillance of Resistance Pathogens (ANSORP) 
The Asian Network for Surveillance of Resistance Pathogens started in 1996 with a study 
investigating pneumococcal resistance in 14 centres in 11 Asian countries. Further projects 
followed on the nasopharyngeal carriage of drug-resistant pneumococci in Asian children, 
community-acquired pneumonia, fluoroquinolone-resistant S. pneumoniae and 
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antimicrobial resistance among enteric pathogens.  The most recent study is focusing on 
community-acquired methicillin-resistant S. aureus, hospital-acquired pneumonia and 
ventilator-associated pneumonia.  
The network has the following vision statements: 
 ANSORP will continue to perform international multicentre research on antimicrobial 
resistance as well as clinical trials in the Asian region. 
 ANSORP will remain an "independent" study group for the international collaboration 
study in the Asian region. 
This research group is co-ordinated from South Korea and uses a WHO approved standard 
for AST, CLSI. ANSORP is support by the Asia Pacific Foundation for Infectious Diseases. 
Isolates collected from these research projects are added to the Asian Bacterial Bank. Since 
2010, more than 45,000 isolates of important bacterial pathogens have been collected from 
14 countries and preserved. The bank operates by charging for sending organisms to 
requesting laboratories. However, no EQA appears to be run by this network.  
Bacterial Infections and Antibiotic Resistant Diseases among Young Children in Low-Income 
Countries (BIRDY) 
The main objective of the BIRDY project is to assess the incidence, and medical and 
economic consequences, of severe childhood and neonatal infections caused by antibiotic 
resistant bacteria. This project uses the Institute Pasteur International Network of 32 
institutions in Europe, North America, the Caribbean, Africa and South East Asia. This project 
is recruiting a cohort of pregnant women and following their children from birth to two 
years to determine the incidence of bacterial infections and resistance in neonates and 
children under two years. The study will also investigate the transmission of multi-resistant 
bacteria either by vertical transmission or by horizontal transmission.  
Global Approach for Biological Research on Infectious Epidemics in Low income countries 
(GABRIEL) 
The GABRIEL research network has investigated resistance in salmonella spp., tuberculosis 
and E.coli. Established in 2006 this research programme is supported by Fondation Mérieux 
laboratories in France and China. As well as conducting research into AMR in specific 
pathogens it also conducts capacity strengthening activities for the network, such as 
workshops on specific topics.  It is also looking to strengthen partner laboratories to achieve 
ISO15189 accreditation.  
International Nosocomial Infection Control Consortium 
This consortium was formed in the late 1990s in Latin America. As part of a more general 
infection control remit the consortium collects AMR data. It now covers 66 countries in four 
continents. As a research focused network, the data it collects is driven by the objectives of 
its on-going research projects.  
SENTRY Antimicrobial Surveillance Program 
The SENTRY is a global programme initiated in 1997 and run by JMI Laboratories. It collects 
isolates from participating laboratories and tests them against a large panel of antibiotics. 
Isolates are obtained from bloodstream, skin and soft tissue, respiratory, urinary tract, 
pathogens from patients hospitalised with pneumonia, intra-abdominal and invasive fungal 
infections. 
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Basic patient and infection demographic information, molecular and phenotypic 
categorisations, and all susceptibility test results are catalogued onto the programme’s 
Microbiology Visualisation Platform. Clients are charged to use this resource (e.g. to test 
specific drugs against specific isolate types or patient demographics).  
Study for Monitoring Antimicrobial Resistance Trends (SMART) 
This surveillance network is supported by Merck & Co. Inc. and has the following objectives: 
 To monitor the in vitro susceptibility of gram-negative bacilli to antimicrobials in intra-
abdominal and urinary tract infections 
 To identify early changes in susceptibility patterns of community- or hospital-acquired 
organisms, including those that produce extended-spectrum beta-lactamases (ESBLs) 
Participating sites collect up to 100 consecutive aerobic and facultative gram-negative bacilli 
from patients with intra-abdominal infections. Duplicate isolates are excluded.  Data is 
collected on the duration of hospitalisation (<48 hours or ≥8 hours) at time of isolate 
recovery. Isolates recovered at <48 hours of hospitalisation are considered community 
acquired. A public accessible database exists which records the details of all project results. 
It has not been possible to confirm if this network is still active. 
AMR surveillance in food and animals 
Food and Waterborne Diseases and zoonoses network (FWD-NET) 
FWD-NET is coordinated by the European Centre for Disease Control (ECDC) with the 
support of a coordination committee consisting of representatives from the EU Member 
States. The committee advises ECDC on ways to strengthen and improve surveillance and 
prevention for food and waterborne diseases and zoonoses in Europe and reviews technical 
documents relevant to the network.  
The mission of FWD-NET is to improve and harmonise the systems in the EU in order to 
tackle multi-country foodborne outbreaks and to increase the scientific knowledge regarding 
aetiology, risk factors and burden of food and waterborne diseases and zoonoses. 
The network has the following specific goals to strengthen surveillance: 
 strengthen the integration of (laboratory) surveillance in humans, food, animals and 
environment  
 support public health microbiology capability building with appropriate laboratory 
methods/techniques to enhance detection of international clusters and outbreaks 
caused by enteric pathogens  
 facilitate detection of and response to multi-country foodborne outbreaks 
As part of this role FWD-NET collects AMR data on salmonella and campylobacter and 
provides EQA for these organisms, including providing support for laboratories that perform 
poorly.  Funds are available for experts to visit sites to train staff in new methodologies and 
for bi-annual AMR network meetings where technical issues are discussed. 
International Surveillance of Reservoirs of Antibiotic Resistance (ISRAR) 
The aim of this programme is to investigate the potential for a global surveillance system to 
track antibiotic resistance in commensal bacteria by collecting global environmental and 
veterinary commensal isolates. This programme is a joint research collaboration of the 
laboratories at the Tufts University School of Medicine Center for Adaptation Genetics and 
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Drug Resistance, Alliance for the Prudent Use of Antibiotics (APUA) country chapters, and 
the U.S. National Biodefense Analysis and Countermeasures Center Biological Threat 
Characterization Program. It has not been possible to confirm if this network is still active. 
World Health Organization Global Salm-Surv  
This project aims to enhance laboratory-based surveillance and outbreak detection and 
response through five components that promote capacity building, collaboration and 
communication. These components comprise International Training Courses, an External 
Quality Assurance System, Focused Regional and National Projects, an Electronic Discussion 
Group, and a Country Databank. Though primarily a capacity strengthening programme it 
encourages the formation of research partnerships, which produce AMR data and also sends 
isolates to a specimen bank. It has not been possible to confirm if this network is still active. 
Inactive Networks 
Our literature search identified a number of AMR surveillance networks that no longer 
appear to be active. These networks are listed in Table 5, alongside their respective area of 
geographical coverage and duration.  Reasons for network discontinuation were not 
examined as a part of this study, although some of the listed networks were time-limited 
projects (e.g. ARPEC). Other networks may possibly have evolved into other regional 
surveillance initiatives (e.g. SAPNA).  
Observations concerning these AMR networks 
 
These networks are very variable in terms of their organisation, geography, operation and 
diseases and organisms covered so it is not possible, or helpful, to directly compare them. 
However, our research has identified some interesting observations and examples of 
innovative practice that may be useful for informing future regional AMR surveillance 
networks:  
• There are strong antimicrobial surveillance networks in the EU and Latin America regions 
(e.g. EARS-NET and ReLARVA).  
• Central Asia has started to develop a regional network based on the EARS-NET model, so 
this region may be considered for future investment to build up their AMR capacity.  
• A significant proportion of AMR activities emanate from research projects and networks. 
These research-based networks may be in a good position to identify laboratories with 
capacity to do good quality AMR surveillance and which could therefore be brought into 
a formal regional AMR network. 
• Research-based AMR networks are driven by project objectives and short-term funding 
cycles. They may therefore find it difficult to take a long-term strategic approach to 
tackling AMR challenges, but clearly have an important role to play in any long-term 
AMR strategy determined by a global or regional agency.  
• It will be important to verify which of these networks are still active and to carry out in-
depth analyses of successful and unsuccessful networks to learn lessons for future 
programmes about how to set up, manage, recruit members and coordinate such 
networks. 
• Despite the high burden of infectious diseases in Africa there appears to be very little 
AMR network coverage across the continent  
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• The SENTRY network has set up a good quality specimen bank, and charges for access 
and testing with isolates obtained from its network. This is an interesting model for 
ensuring financial sustainability of the network, which it may be possible to replicate in 
other AMR networks that collect high quality data and samples.  
 
Findings on educational resources for supporting anti-microbial 
resistance surveillance 
 
We identified a limited number of educational resources relevant for supporting AMR 
surveillance (table 6) which are accessible and freely available as on-line tools, slide sets or 
downloadable pdf documents.  Several were available through the networks discussed 
above (see table 1). We also identified reports of international and national AMR 
surveillance activities (e.g. from the EU but these were not included in this section as they 
did not specifically provide educational resources to support AMR surveillance. 
http://ecdc.europa.eu/en/publications/surveillance_reports/Pages/index.aspx and Canada 
http://nccid.ca/collection/antimicrobial-resistance/)  
The scope of most of the resources concerned general issues to do with AMR surveillance 
though not all of them were designed explicitly for this purpose (e.g. World Bank 2002 is 
concerned with public health surveillance in general). Some focused on specific infections 
such as lower respiratory tract infections, tuberculosis. Salmonella, E. coli and Listeria 
monocytogenes or on specific target groups such as community paediatricians, laboratories 
or national data managers. A couple of websites functioned as resource centres bringing 
together searchable published articles, policies, reports and web tools to facilitate actions on 
antibiotic resistance or hosting a platform for exchanging information, priorities and results 
on infectious diseases and AMR surveillance.  
The content of the educational resources was heterogeneous and varied from generic topics 
such as how to design a programme for integrated surveillance of antimicrobial resistance 
and how to collect and report AMR data, to specific topics such as protocols for individual 
organisms. The most comprehensive resources and up to date are the Integrated 
Surveillance of Antimicrobial Resistance Guidance from the WHO Advisory Group (2013) and 
the ReAct - Action on Antibiotic Resistance toolbox from Uppsala University though this is 
not exclusively concerned with surveillance. Different players involved in AMR surveillance 
will require different types of educational resources with content orientated towards their 
needs. The WHO and ReAct documents provide helpful comprehensive information and 
would be a good basis for developing future additional resources. The nature of these 
resources would need to be determined through consultations with the different cadres of 
AMR surveillance players and mechanisms for making sure that these resources were 
regularly updated and revised would need to be ensured.  
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Table 1: International and Regional Networks Identified 
Network 
Acronym 
Full Network Name 
ANSORP Asian Network for Surveillance of Resistance Pathogens 
BIRDY Bacterial Infections and antibiotic Resistant Diseases among Young children in low-Income countries 
CDC GDD US CDC Global Disease Detection programme 
CAESAR Central Asian and Eastern European Surveillance of AMR Network 
EARSnet European Antimicrobial Resistance Surveillance network 
FWDnet Food and Waterborne Diseases and zoonoses network 
GABRIEL Global Approach for Biological Research on Infectious Epidemics in Low income countries 
GARPEC Global Antimicrobial Resistance, Prescribing, and Efficacy Among Neonates and Children 
GASP Gonococcal Antimicrobial Surveillance Program 
GFN Global Foodborne infections Network 
GLOBAL Project WHO Global Project on anti-TB drug resistance surveillance 
HIVResNet Global HIV Drug Resistance Surveillance Network 
INICC International Nosocomial Infection Control Consortium 
ISRAR International Surveillance of Reservoirs of Antibiotic Resistance 
ReLAVRA Red Latinoamericana de Vigilancia a las Resistencias Antimicrobianis 
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Network 
Acronym 
Full Network Name 
SENTRY SENTRY Antimicrobial Surveillance Program 
SIREVA System of Networks for Surveillance of the Bacterial Agents Responsible for Pneumonia and 
Meningitis 
SMART Study for Monitoring Antimicrobial Resistance Trends 
WHO GSS WHO Global Salmonella Surveillance 
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Table 2. Detailed descriptions: geographic coverage, size, coordinating centre and anti-microbial sensitivity (AST) standard 
Network Participating Countries No. of 
Laboratories 
Coordinating 
Centre 
AST 
Standard 
ANSORP China, Taiwan, Vietnam, South Korea, Hong Kong, India, Japan, Malaysia, 
Philippines, Sri Lanka, Thailand, Singapore, Indonesia, Philippine, Saudi 
Arabia 
23 Samsung 
Medical Centre, 
Seoul, South 
Korea 
CLSI 
BIRDY* Madagascar, Senegal, Cambodia (anticipated expansion) 3 + (if needed) Institut Pasteur No Data 
CDC GDD GDD supported over in over 50 countries through CDC Centres located in: 
Bangladesh, Guatemala, Kazakhstan, China, Egypt, India, Kenya, South 
Africa, Georgia and Thailand. 
10 Disease 
Control centres 
CDC No Data 
CAESAR Albania, Armenia, Azerbaijan, Belarus, Bosnia and Herzegovina, Georgia, 
Kyrgyzstan, Montenegro, the Republic of Moldova, the Russian 
Federation, Serbia, Switzerland, Tajikistan, the former Yugoslav Republic 
of Macedonia, Turkey, Turkmenistan and Uzbekistan and Kosovo  
Multiple WHO 
Collaborating 
Centre for AMR 
Epidemiology 
and Surveillance 
at the National 
Institute for 
Public Health 
and the 
Environment, 
the Netherlands 
EUCAST, CLSI 
EARS - Net All 28 EU Member States + Iceland & Norway 900+ European 
Centre for 
Disease 
EUCAST 
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Network Participating Countries No. of 
Laboratories 
Coordinating 
Centre 
AST 
Standard 
Prevention and 
Control (ECDC) 
FWD – 
Net* 
All 28 EU Member States 28+ ECDC EUCAST 
GABRIEL Cameroon, Mali, Madagascar, Brazil, Paraguay, Haiti, Laos, China, 
Bangladesh, Lebanon, Cambodia 
 
18 Emerging 
Pathogens 
Laboratory 
(EPL), Lyon 
(France) and 
Christophe 
Mérieux 
Laboratory, 
Beijing (China) 
No Data 
GARPEC South Africa, UK, Italy, Turkey, China, Thailand, USA, Brazil, Argentina, 
Australia.  
12   
GASP Australia, Austria, Argentina, Bahrain, Belgium, Bolivia, Brazil, Bhutan, 
Brunei, Cambodia, Canada, Chile, China/Hong Kong, Columbia, Côte 
d'Ivoire, Cuba, Cyprus, Denmark, Ecuador, El Salvador, Fiji, Finland, 
France, Germany, Greece, Hungary, India, Indonesia, Ireland, Italy, Japan, 
Korea, Kenya, Latvia, Madagascar, Malaysia, Malta, Mongolia, Morocco, 
Namibia, New Zealand, Papua New Guinea, Paraguay, Peru, Philippines, 
Portugal, Romania, Russia, Singapore, Slovakia, Slovenia, Spain, South 
Africa, Sri Lanka, Sweden, Tanzania, Thailand, The Netherlands, Tonga, 
No data WHO  
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Network Participating Countries No. of 
Laboratories 
Coordinating 
Centre 
AST 
Standard 
Norway, Uganda, Uruguay, Venezuela, Viet Nam United Kingdom, USA, 
Zimbabwe 
GFN 184 member states and territories Multiple WHO CLSI, NCCLS 
GLOBAL 
Project 
114 countries worldwide Multiple WHO N/A 
HIVResNet Participating countries worldwide can send samples to 33 accredited 
laboratories for analysis. 
33 WHO N/A 
INICC Egypt, Kenya, Libya, Morocco, Nepal, Sudan, Tunisia, Argentina, Bolivia, 
Botswana, Brazil, Columbia, Costa Rica, Cuba, Ecuador, El Salvador, 
Honduras, Mexico, Nicaragua, Panama, Paraguay, Peru, Puerto Rico, 
Dominican Republic, Uruguay, Venezuela, China, Georgia, India, 
Indonesia, Iran, Jordan, Saudi Arabia, Kuwait, Lebanon, Malaysia, 
Mongolia, Pakistan, Philippines, Qatar, Singapore, Sri Lanka, Oman, 
Thailand, Turkey, UAE, Vietnam, Yemen, Bulgaria, Cyprus, Greece. 
Kosovo, Lithuania, Macedonia, Poland, Romania, Russia, Serbia, Slovakia, 
Spain, Ukraine. 
2000+   
ISRAR APUA Global Chapters in conjunction with local laboratories in India, 
South Korea, Turkey, Thailand, Vietnam, Bangladesh, Georgia, and 
Uganda 
No Data Tufts University 
School of 
Medicine Center 
No Data 
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Network Participating Countries No. of 
Laboratories 
Coordinating 
Centre 
AST 
Standard 
ReLAVRA Argentina, Bolivia, Brazil, Bahamas, Cuba, Chile, Barbados, Ecuador, 
Columbia, Jamaica, El Salvador, Costa Rica, Trinidad and Tobago, 
Guatemala, Mexico, St Lucia, Nicaragua, Peru, Paraguay, Venezuela.   
519 National 
Institute of 
Infectious 
Diseases of 
Argentina 
CLSI 
SENTRY 35 nations.  150 labs Iowa, United 
States and 
Adelaide, 
Australia 
 
CLSI, NCCLS 
SIREVA Argentina, Brazil, Chile, Colombia, Mexico, Uruguay, Bolivia, Costa Rica, 
Cuba, Dominican Republic, Ecuador, El Salvador, Guatemala, Honduras, 
Nicaragua, Panama, Paraguay, Peru, and Venezuela 
471 PAHO No data 
SMART Canada, USA, Mexico, Guatemala, Dominican Republic, Panama, 
Columbia, Ecuador, Venezuela, Puerto Rico, Chile, Argentina, Brazil, 
South Africa, Morocco, Tunisia, Spain, France, UK, Lithuania, Czech 
Republic, Latvia, Estonia, Germany, Romania, Serbia, Croatia, Greece, 
Georgia, Hungary, Kazakhstan, South Korea, China, Taiwan, Vietnam, 
Thailand, Philippines, Malaysia, Singapore, New Zealand, Australia, India, 
Jordan, Israel, Lebanon, UAE, Saudi Arabia.  
282 hospital 
sites 
Merck & Co., 
Inc., 
Whitehouse 
Station, NJ, USA 
CLSI 
WHO GSS No Data No Data No Data CLSI 
* Results verified by a network representative 
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Table 3. Detailed descriptions: organisms and associated drug classes under surveillance, specimen types collected 
Network Organisms Drug Class Specimens 
ANSORP* Acinetobacter sp. Imipenem, meropenem, colistin, tetracycline, ciprofloxacin, 
rifampicin, cefepime, ceftazidime, amikacin, 
piperalicillin/tazobactam Tigecycline, ampicillin-sulbactam 
 
Stenotrophomonas maltophilia Imipenem, meropenem, colistin, tetracycline, ciprofloxacin, 
rifampicin, cefepime, ceftazidime, amikacin, 
piperalicillin/tazobactam Tigecycline 
 
Pseudomonas aeruginosa Imipenem, meropenem, colistin, tetracycline, ciprofloxacin, 
rifampicin, cefepime, ceftazidime, amikacin, 
piperalicillin/tazobactam Tigecycline 
 
Enterococcus sp. vancomycin, teicoplanin, ampicillin, tetracycline, erythromycin, 
ciprofloxacin, rifampicin, streptomycin, gentamicin, linezolid 
 
Escherichia coli ampicillin, gentamicin, ciprofloxacin, ceftazidime, AZT, Imipenem, 
Tigecycline, trimethoprim-sulfamethoxazole, cefotaxime, 
piperalicillin/tazobactam, amikacin, ampicillin-sulbactam, 
ertapenem 
 
Klebsiella pneumoniae ampicillin, GEN, ciprofloxacin, ceftazidime, AZT, Imipenem, 
Tigecycline, trimethoprim-sulfamethoxazole, cefotaxime, 
piperalicillin/tazobactam, amikacin, ampicillin-sulbactam, 
ertapenem 
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Network Organisms Drug Class Specimens 
Enterobacter sp. ampicillin, gentamicin, ciprofloxacin, ceftazidime AZT, Imipenem, 
Tigecycline, trimethoprim-sulfamethoxazole, cefotaxime, 
piperalicillin/tazobactam, amikacin, ampicillin-sulbactam 
 
Proteus sp. ampicillin, gentamicin, ciprofloxacin, ceftazidime, AZT, Imipenem, 
Tigecycline, trimethoprim-sulfamethoxazole, cefotaxime, 
piperalicillin/tazobactam 
 
Citrobacter sp. ampicillin, gentamicin, ciprofloxacin, ceftazidime, AZT, Imipenem, 
Tigecycline, trimethoprim-sulfamethoxazole, cefotaxime, 
piperalicillin/tazobactam 
 
Staphylococcus aureus   oxacillin, penicillin, ciprofloxacin, clindamycin, erythromycin, 
vancomycin, tetracycline, trimethoprim-sulfamethoxazole, 
gentamicin, rifampicin, linezolid 
 
Streptococcus pneumoniae penicillin, amikacin, amoxicilin-clavulanic acid, ceftriaxone, 
cefuroxime, erythromycin, azithromycin, clarithromycin, 
levofloxacin, moxifloxacin, gemifloxacin, ciprofloxacin, CD, 
trimethoprim-sulfamethoxazole vancomycin, linezolid, Tigecycline, 
imipenem, rifampicin, tetracycline 
 
BIRDY All infections in <2 year olds in 
cohort 
amikacin; ampicillin, amoxicillin, amoxicilin-clavulanic acid, 
ampicillin-sulbactam, azithromycin, ceftazidime;   
clindamycin, ciprofloxacin, colistin; CLA, clarithromycin, cefepime, 
ceftriaxone, cefotaxime, erythromycin;  
all 
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Network Organisms Drug Class Specimens 
ertapenem, cefuroxime, gentamicin, gemifloxacin, Imipenem, 
levofloxacin, linezolid, meropenem;  
moxifloxacin, oxacillin, penicillin, piperacillin-tazobactam, rifampicin, 
streptomycin, teicoplanin, tetracycline;  
Tigecycline, trimethoprim-sulfamethoxazole, vancomycin   
CDC GDD No data No data No data 
CAESAR* Streptococcus pneumoniae Penicillin Oxacillin (screen) Erythromycin Norfloxacin (screen) OR 
Levofloxacin OR Moxifloxacin 
Blood or 
cerebrospinal fluid 
as appropriate 
(CSF) 
Staphylococcus aureus Cefoxitin (disk screen) Vancomycin 
Enterococcus faecalis Ampicillin Gentamicin-High Vancomycin 
Enterococcus faecium Ampicillin Gentamicin-High Vancomycin 
Escherichia coli and Klebsiella 
pneumoniae 
Piperacillin-tazobactam OR Amoxicillin-clavulanic acid Gentamicin 
OR Tobramycin OR Amikacin Ceftriaxone OR Cefotaxime OR 
Ceftazidime Ciprofloxacin OR Ofloxacin OR Levofloxacin Meropenem 
OR Imipenem OR Ertapenem 
Pseudomonas aeruginosa Piperacillin/tazobactam Ceftazidime Cefipime Ciprofloxacin OR 
Levofloxacin Gentamicin OR Tobramycin OR Amikacin Imipenem OR 
Meropenem 
Acinetobacter species Fluoroquinolones, Aminoglycosides, Carbapenems, Amikacin, 
Polymyxins 
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Network Organisms Drug Class Specimens 
EARS - Net Escherichia coli Aminopenicillins, Fluoroquinolones, Third-generation 
cephalosporins, Aminoglycosides, Carbapenems, Polymyxins 
Blood or CSF as 
appropriate 
Staphylococcus aureus  MRSA, Rifampicin, Fluoroquinolones, Linezolid, Vancomycin, 
Daptomycin 
Enterococcus faecalis & faecium High-level aminoglycoside resistance, Vancomycin, Aminopenicillins, 
Teicoplanin, Linezolid 
Klebsiella pneumoniae Fluoroquinolones, Third-generation cephalosporins, 
Aminoglycosides, Carbapenems, Polymyxins 
Streptococcus pneumoniae Penicillins, Macrolides, Fluoroquinolones, Third-generation 
cephalosporins 
Pseudomonas aeruginosa Piperacillin-tazobactam, Ceftazidime, Fluoroquinolones, 
Aminoglycosides, Carbapenems, Amikacin, Polymyxins 
Acinetobacter spp Fluoroquinolones, Aminoglycosides, Carbapenems, Amikacin, 
Polymyxins 
FWD – Net* Salmonella Aminoglycosides, Aminopenicillins, Amphenicols, Carbapenems, 
Cephalosporins, Dihydrofolate reductase inhibitors, Macrolides, 
Polymyxins, Quinolones, Sulphonamides, Tetracyclines 
Not standardised 
Campylobacter Aminoglycosides, Macrolides, Quinolones, Tetracyclines 
GABRIEL* Mycobacterium Tuberculosis Rifampicin and Isoniazid plus fluoroquinolone and at least one of 
three injectable second-line drugs (i.e., amikacin, kanamycin, or 
capreomycin) 
Blood, sputum or 
faeces as 
appropriate 
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Network Organisms Drug Class Specimens 
Respiratory pathogens (viral and 
bacteria) 
no test for the moment 
E coli ETEC Ampicillin, Azithromycin, Ciprofloxacin, Ceftriaxone, Doxycline , 
Erythromycin, Nalidixic Acid, Norfloxacin , Streptomycin , 
Sulfomethoxazole trimethoprim, Tetracyline, Cefixime, Amikacin 
Salmonella typhi Ampicillin - Cotrimoxazole - Chloramphenicol - Ciprofloxacin - 
Ceftriaxone 
GARPEC    
GASP N. gonorrhoeae azithromycin, cephalosporins, quinolones  
GFN    
GLOBAL Project M.tuberculosis Rifampicin, streptomycin, ethambutol, isoniazid, fluoroquinolones, 
amikacin, kanamycin, or capreomycin 
Predominantly 
sputum  
HIVResNet HIV  Blood 
INICC Varies based on research projects 
being carried out 
Varies based on research projects being carried out Varies based on 
research projects 
being carried out 
ISRAR    
ReLAVRA Enterococcus spp.  Blood, urine, 
sputum  (all types) 
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Network Organisms Drug Class Specimens 
 Klebsiella pneumoniae Imipenem, third generation cephalosporins  
 Acinetobacter spp.   
 Pseudomonas aeruginosa,    
 Streptococcus, (several species both 
community acquired and hospital 
based) 
  
 Staphylococcus aureus Oxacilin  
 Escherichia coli Ciprofloxacin, Nitrofurantoin, Co-trimoxazole, Cefalotin  
 Enterobacter spp.   
 Salmonella spp.   
 Shigella spp.   
 Vibrio cholerae    
 Escherichia coli   
 Neisseria meningitidis   
 Neisseria gonorrhoeae Ciprofloxacin, penicillin, tetracycline, cefotaxime/cefatriaxone   
 Streptococcus pneumoniae   
 Campylobacter   
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Network Organisms Drug Class Specimens 
 β haemolytic streptococcus   
SENTRY* Acinetobacter spp. Cephalosporins, other β-lactams, fluoroquinolones, 
aminoglycosides, tetracycline, Trimethoprim/sulfamethoxazole, 
Polymixin B 
Blood, sputum, skin 
cell, 
intraabdominal 
 Enterobacter spp. Cephalosporins, other β-lactams, fluoroquinolones, 
aminoglycosides, tetracycline, Trimethoprim/sulfamethoxazole, 
Polymixin B 
 
 Escherichia coli Cephalosporins, other β-lactams, fluoroquinolones, 
aminoglycosides, tetracycline, Trimethoprim/sulfamethoxazole, 
Polymixin B 
 
 Haemophilus influenzae Cephalosporins, other β-lactams, macrolides, fluoroquinolones, 
aminoglycosides, tetracycline, Trimethoprim/sulfamethoxazole, 
Choranphenicol 
 
 Klebsiella pneumoniae Cephalosporins, other β-lactams, fluoroquinolones, 
aminoglycosides, tetracycline, Trimethoprim/sulfamethoxazole, 
Polymixin B 
 
 Moraxella catarrhalis β-lactams, macrolides, fluoroquinolones, tetracycline, 
Trimethoprim/sulfamethoxazole, chloramphenicol 
 
 Proteus spp. Cephalosporins, other β-lactams, fluoroquinolones, 
aminoglycosides, tetracycline, Trimethoprim/sulfamethoxazole, 
Polymixin B 
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Network Organisms Drug Class Specimens 
 Pseudomonas aeruginosa Cephalosporins, other β-lactams, fluoroquinolones, 
aminoglycosides, tetracycline, Trimethoprim/sulfamethoxazole, 
Polymixin B 
 
 Salmonella spp. Cephalosporins, other β-lactams, fluoroquinolones, 
aminoglycosides, tetracycline, Trimethoprim/sulfamethoxazole 
 
 Serratia spp. Cephalosporins, other β-lactams, fluoroquinolones, 
aminoglycosides, tetracycline, Trimethoprim/sulfamethoxazole, 
Polymixin B 
 
 Shigella spp. Cephalosporins, other β-lactams, fluoroquinolones, 
aminoglycosides, tetracycline, Trimethoprim/sulfamethoxazole 
 
 Stenotrophomonas maltophilia Cephalosporins, other β-lactams, fluoroquinolones, 
aminoglycosides, tetracycline, Trimethoprim/sulfamethoxazole, 
Polymixin B 
 
 Staphylococcus aureus Cephalosporins, other β-lactams, MLS, fluoroquinolones, 
gentamicin, rifampin,chloramphenicol, tetracycline, doxycycline, 
Trimethoprim/sulfamethoxazole, vancomycin, teicoplanin, 
quinupristan/dalfopristin, linezolid 
 
 Coagulase Negative Staphylococcus  Cephalosporins, other β-lactams, MLS, fluoroquinolones, 
gentamicin, rifampin,chloramphenicol, tetracycline, doxycycline, 
Trimethoprim/sulfamethoxazole, vancomycin, teicoplanin, 
quinupristan/dalfopristin, linezolid 
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Network Organisms Drug Class Specimens 
 Enterococcus spp. β-lactams, MLS, fluoroquinolones, levofloxacin, gentamicin, 
streptomycin, rifampin, chloramphenicol, tetracycline, doxycycline, 
Trimethoprim/sulfamethoxazole, vancomycin, teicoplanin, 
quinupristan/dalfopristin, linezolid 
 
 Burkholderia cepacia Cephalosporins, other β-lactams, fluoroquinolones, 
aminoglycosides, tetracycline, Trimethoprim/sulfamethoxazole 
 
 Citrobacter spp. Cephalosporins, other β-lactams, fluoroquinolones, 
aminoglycosides, tetracycline, Trimethoprim/sulfamethoxazole 
 
 Morganella morgannii Cephalosporins, other β-lactams, fluoroquinolones, 
aminoglycosides, tetracycline, Trimethoprim/sulfamethoxazole 
 
SIREVA Streptococcus pneumonia, 
Haemophilus influenza, Neisseria 
meningitidis. 
No Data CSF, blood, and 
pleural fluid 
SMART Gram-negative isolates Ertapenem, imipenem, cefepime, ceftazidime, ceftazidime-clavulanic 
acid, cefoxitin, ciprofloxacin, amikacin, levofloxacin, cefotaxime, 
cefotaxime-clavulanic acid, piperacillin-tazobactam, ampicillin-
sulbactam and ceftriaxone 
intra-abdominal 
infections and 
urinary-tract 
infections 
WHO GSS Salmonella, Campylobacter No data No data 
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Table 4. Detailed descriptions: types of support services available to network members 
Network EQA Training Technical Assistance 
ANSORP No data No data No data 
BIRDY No Data No Data No Data 
CDC GDD No Data No Data  No Data 
CAESAR* EQA is provided annually through UK-
NEQAS 
Training in the form of national workshops 
and multi-country workshops is provided. 
Main focus is on microbiologic methods (in 
particular EUCAST), data management 
(data collection, IT aspects of data capture 
and transfer, data quality control, data 
security) and epidemiology (interpretation 
of AMR surveillance data and sources of 
bias).   
Technical support is provided  
 
EARS - Net EQA is provided annually through UK-
NEQAS 
No data No data 
FWD – Net* ECDC funds an annual AST EQA for 
Salmonella and Campylobacter based 
on the set up of the EU protocol. It 
includes 8 strains of each organism 
and covers the priority and the 
optional list of antimicrobials. In 
addition to phenotypic AST, it also 
covers detection and confirmation of 
Financial support is available for experts to 
visit laboratories in another country to 
learn new methods during a few days. This 
requires a formal application to be 
submitted to ECDC by the expert 
ECDC arrange bi-annual AMR meetings for 
the network where technical issues are 
discussed as one of several topics. At these 
meetings, the AST EQA organiser also 
presents the overall results of the EQA and 
feedback on problematic issues. Labs that 
experience problems in the EQA can also 
contact the organiser directly to get 
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Network EQA Training Technical Assistance 
ESBL‐, acquired AmpC, and 
carbapenemase-producing 
Salmonella spp and resistance gene 
testing as well as species 
determination of Campylobacter. The 
AST EQA is also offered for free to 
the EU enlargement countries 
assistance in finding the source behind the 
problem. 
GABRIEL* For Tuberculosis, a panel of sensible 
and resistance strains are sent to the 
members, and this panel is tested in 
blind by LIPA assay. For pneumonia, 
we have also a panel control for the 
respiratory pathogens to control the 
tests perform on site 
Different types of training are organised: 
tutorial training to allow technology 
transfer and workshop to improve the 
skills of the members (in molecular 
biology, epidemiology, bioinformatics …) 
Fondation Merieux analyse the raw data 
and provide advices when necessary. They 
go on site for training before to start a 
research study to check the capacity of the 
human resources 
GARPEC    
GASP No Data No data  No data 
GFN    
GLOBAL Project Supra-national laboratories provide 
EQA services  
 Various development projects, 
predominantly US funded, provide 
technical assistance to national TB 
programmes.  
HIVResNet No Data No data Various development projects, 
predominantly US funded, provide 
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Network EQA Training Technical Assistance 
technical assistance to national HIV 
programmes. 
INICC  INICC offers training in the application of 
tools to consolidate capacities locally, 
targeted specifically at doctors, nurses, 
pharmacists, ancillary staff and healthcare 
facilities’ administrators and managers in 
the private and public sectors.  INICC is 
working on the design of the appropriate 
technology for the analysis of healthcare-
associated infection process and outcome. 
 
ISRAR    
ReLAVRA    
SENTRY* No EQA No training Network members have access to all the 
data 
SIREVA EQA – (rechecking of isolates and 
proficiency testing) by the National 
Centre for Streptococcus, Edmonton, 
Alberta, Canada through three 
quality control centres in Brazil, 
Colombia & Mexico. 
 Training of lab staff Performance evaluations 
SMART No Data No data No data 
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Network EQA Training Technical Assistance 
WHO GSS Yes –annual cycles Yes - offers international training courses 
at nine sites in the six WHO regions to 
achieve its goal 
Yes 
* Results verified by a network representative 
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Table 5. Discontinued AMR surveillance networks 
Acronym Full Network Name Coverage Duration 
ARMed Antibiotic Resistance Surveillance and Control in the Mediterranean Region Mediterranean 2003-2006 
ARPEC Antibiotic Resistance and Prescribing in European Children Europe 2010-2016 
EANMAT East Africa Network for Monitoring Antimalarial Treatment East Africa 1997-2006 
INSPEAR International Network for the Study and Prevention of Emerging Antimicrobial Resistance International 1998-? 
MYSTIC Meropenem Yearly Susceptibility Test Information Collection International 1997-2008 
netSPEAR Network for Surveillance of Pneumococcal Disease in the East African Region East Africa 2003-2009 
SAPNA South Asian Pneumococcal Network Alliance South Asia 2004-2008 
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Table 6. Educational resources concerning AMR networks 
Resource/ 
linked network 
Type of Resource / intended use Access Website and contacts 
React toolbox/ 
ReAct 
A web-based resource for taking action on 
antibiotic resistance. Throughout the toolbox a 
narrative text guides the user on how to work 
with the problem, combining practical advice 
with examples from the field and providing links 
to external resources that may be useful in 
different settings  
The Toolbox is intended for use by those already 
working with antibiotic resistance in some way, 
or are interested in taking action.  The main 
target audience for the Toolbox is health care 
professionals, civil society organisations and 
policy makers in low-and middle-income 
countries. 
Focus on antibiotic resistance rather than 
surveillance networks 
Free, online web based- collaborative. You 
may copy and re-use content on the ReAct 
Toolbox website (that are not materials 
posted from and/or clearly cited from 
other sources), provided always that you 
give proper credit to ReAct.  
http://www.reactgroup.org/toolbox/ 
ReAct - Action on Antibiotic Resistance 
Uppsala University 
Box 256, SE-751 05 Uppsala, Sweden 
Phone: +46 (0)18 471 66 07 
Fax: +46 (0)18 471 66 09 
E-mail: react@medsci.uu.se 
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Resource/ 
linked network 
Type of Resource / intended use Access Website and contacts 
React resources 
/ ReAct  
The resource centre includes a selection of 
published articles, reports and web tools to 
facilitate action on antibiotic resistance. Facts 
and Tools 
Policy and Reports 
ReAct-produced material 
Reference Library 
The Resource Centre is a searchable database, a 
web-based “library”, to help people gain easy 
access to scientific articles, policy documents and 
reports related to antibiotic resistance. 
Free, online http://www.reactgroup.org/resource-
center.html 
 
Update: Link no longer active. Interested 
parties may wish to contact the ReAct 
group using the details above 
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Resource/ 
linked network 
Type of Resource / intended use Access Website and contacts 
Arpec  Web based training programme will be 
developed by the ARPEC team. This will provide a 
range of educational modules on optimal 
antibiotic prescribing and antimicrobial 
resistance. Eventually it will be possible to modify 
the online content to produce country specific 
training, potentially containing data obtained 
from our collaborators. It is anticipated that 
making the training modules more relevant to 
the different countries will improve the training 
dissemination through ESPID and the EAP. 
 
An Educational Group was formed within ARPEC 
to tackle the issue of training in antibiotic use for 
children in Europe. 
A basic slide set directed at paediatricians in 
training likely to become community prescribers 
has been produced and is available online. 
Collaboration with ESPID (Education Committee) 
will lead to the development and implementation 
of an online training course on antibiotic 
utilisation for children. 
 
http://penta-id.org/training/past-
projects/arpec-educational-tool/ 
 
CDC-GDD Shareable resources showcase the depth and 
diversity of the Global Disease Detection program 
 
http://www.cdc.gov/globalhealth/health
protection/gdd/resources/index.html 
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Resource/ 
linked network 
Type of Resource / intended use Access Website and contacts 
as we work with countries to build capacity to 
find and stop outbreaks around the world 
Integrated 
Surveillance of 
Antimicrobial 
Resistance 
Guidance from 
a WHO Advisory 
Group / WHO 
Pdf document 
To provide WHO Member States with key 
information on designing a programme for 
integrated surveillance of antimicrobial 
resistance. 
Online http://apps.who.int/iris/bitstream/10665
/91778/1/9789241506311_eng.pdf  
Antimicrobial 
resistance 
(AMR) 
reporting 
protocol 2015 / 
EARS-net 
Pdf document 
data collection guidelines for reporting countries’ 
data managers 
Downloadable document http://ecdc.europa.eu/en/activities/surve
illance/EARS-Net/Documents/2015-EARS-
Net-reporting-protocol.pdf  
 GLOBE portal 
(Global Link for 
Biomedical 
Expertise 
Online) / 
GABRIEL 
A dedicated website for the network members to 
exchange and communicate their priorities and 
research results on infectious diseases and more 
particularly on the lower respiratory tract 
infections and tuberculosis. 
 
http://gabriel.globe-
network.org/en/gabriel/resources 
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Resource/ 
linked network 
Type of Resource / intended use Access Website and contacts 
standard 
molecular 
typing protocols 
/ FWD-net 
For PFGE on Salmonella (excluding S. 
Tyhpmurium and S. Enteritidis) and E. coli 
isolates:  
PulseNet International 2013-03 PFGE protocol for 
Salmonella and E. coli  
  
For PFGE on Listeria monocytogenes isolates: 
PulseNet PFGE protocol for Listeria 
monocytogenes 
 
Alternative, comparable method for PFGE-typing 
of Listeria monocytogenes isolates is published by 
the European Union Reference Laboratory for 
Listeria monocytogenes 
 
 
http://ecdc.europa.eu/en/healthtopics/f
ood_and_waterborne_disease/surveillan
ce/Pages/index.aspx 
 Public health 
surveillance 
toolkit 
  
http://siteresources.worldbank.org/INTP
H/Resources/376086-
1133371165476/PHSurveillanceToolkit.p
df 
Core Elements 
of Hospital 
Antibiotic 
  
https://www.cdc.gov/getsmart/healthcar
e/pdfs/core-elements.pdf 
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Resource/ 
linked network 
Type of Resource / intended use Access Website and contacts 
Stewardship 
Programs 
National 
Healthcare 
Safety Network 
(NHSN) 
  http://www.cdc.gov/nhsn/acute-care-
hospital/aur/  
Guide for 
establishing 
laboratory-
based 
surveillance for 
antimicrobial 
resistance 
  
http://apps.who.int/medicinedocs/docu
ments/s20135en/s20135en.pdf  
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Annex 1. Terms of reference 
Supporting Surveillance Capacity for Antimicrobial Resistance: Regional Networks and 
Educational Resources 
This document has been drafted in response to the Request for Proposal (RFP) issued by the 
Wellcome Trust on 28 January 2016, titled: ‘Fleming Fund: supporting surveillance capacity 
for antimicrobial resistance’. The RFP contained three themes and this proposal is to address 
the terms of reference (ToR) for one of them, specifically ‘an analysis of networks and 
education resources supporting drug resistant infection surveillance in low and middle income 
countries (LMICs)’.  The ToR presented two objectives (described in full in 2.1 and 2.2 below) 
which, in broad terms, require the identification and assessment of drug resistance 
surveillance ‘networks’ in LMICs and of available ‘educational resources’ designed to support 
effective implementation of such networks.    
We would define a drug resistance surveillance network as a group of institutions (nationally) 
or countries (regionally/globally) that gather, analyse, compile and share the results of any 
aspect of antimicrobial resistance (e.g. antimicrobial resistance, antimicrobial use and 
antimicrobial quality). The Capacity Research Unit (CRU), Liverpool School of Tropical 
Medicine (LSTM), has extensive experience assessing laboratory and research systems within 
LMICs and identifying site- and system-specific capacity strengthening pathways. As such, we 
believe we are strongly positioned to meet the stated ToR objectives which we would achieve 
by drawing on our existing expertise and networks to complete the following five activities: 
1 Identify drug resistance surveillance networks through a systematic review of the 
published and grey literature and through consultation with existing contacts in LMICs 
and relevant research and development organisations. 
2 Assess the scope, strengths and weaknesses of each identified network against a study-
specific evaluation matrix. The matrix will be informed by existing surveillance system 
benchmarks such as the WHOs Global Antimicrobial Resistance Surveillance System 
(GLASS) and the OASIS tool for assessing epidemiological surveillance systems. The 
assessment of each surveillance network will be based on information obtained during 
the aforementioned review of published and grey literature and through key informant 
interviews with members from each network or individuals with working knowledge of a 
network. 
3 Produce a report comparing and contrasting each network according to the evaluation 
matrix, identifying best performing networks regionally and detailing key 
recommendations for strengthening regional surveillance networks. 
4 Identify existing educational resources to support strengthening of current drug resistant 
infection surveillance systems through a systematic review of the published and grey 
literature, through consultation with existing contacts in LMICS and relevant research and 
development organisations and during the aforementioned key informant interviews with 
network members. 
5 Produce a report detailing the identified education resources, their respective scope (i.e. 
which component(s) of a surveillance system they are designed to support) and how to 
access them. The report will also detail current gaps in the available education resources, 
with respect to both scope and access.    
